Clinical Trial Update: Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of GS-9901 in adults with relapsed or refractory follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, or small lymphocytic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• GS-9901

Snippet

Sponsor: Gilead Sciences | Conditions: Follicular Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED